Invasion by colorectal carcinomas is characterized by an epithelial-mesenchymal transition (EMT)-like dedifferentiation of the tumor cells. However, a redifferentiation towards an epithelial phenotype, resembling a mesenchymal-epithelial transition, is detectable in metastases. This indicates that malignant progression is based on dynamic processes, which cannot be explained solely by irreversible genetic alterations, but must be additionally regulated by the tumor environment. The main oncoprotein in colorectal cancer is the Wnt pathway effector β-catenin, which is overexpressed due to mutations in the APC tumor suppressor in most cases. EMT of the tumor cells is associated with a nuclear accumulation of the transcriptional activator β-catenin, which is reversed in metastases. Nuclear β-catenin is involved in two fundamental processes in embryonic development: EMT and stem cell formation. Accumulating data demonstrate that aberrant nuclear expression of β-catenin can also confer these two abilities to tumor cells, thereby driving malignant tumor progression.

Keywords:
Colorectal cancer, EMT, MET, β-catenin, Tumor invasion
1.
Al-Hajj, M., M.W. Becker, M. Wicha, I. Weissman, M.F. Clarke (2004) Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14: 43–47.
2.
Barker, N., G. Huls, V. Korinek, H. Clevers (1999) Restricted high level expression of Tcf-4 protein in intestinal and mammary gland epithelium. Am J Pathol 154: 29–35.
3.
Barker, N., A. Hurlstone, H. Musisi, A. Miles, M. Bienz, H. Clevers (2001) The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. EMBO J 20: 4935–4943.
4.
Bates, R.C., A.M. Mercurio (2003) Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 14: 1790–1800.
5.
Batsche, E., C. Muchardt, J. Behrens, H.C. Hurst, C. Cremisi (1998) RB and c-Myc activate expression of the E-cadherin gene in epithelial cells through interaction with transcription factor AP-2. Mol Cell Biol 18: 3647–3658.
6.
Behrens, J. (1999) Cadherins and catenins: Role in signal transduction and tumor progression. Cancer Metastasis Rev 18: 15–30.
7.
Bienz, M., H. Clevers (2000) Linking colorectal cancer to Wnt signaling. Cell 103: 311–320.
8.
Brabletz, T., K. Herrmann, A. Jung, G. Faller, T. Kirchner (2000) Expression of nuclear beta-catenin and c-myc is correlated with tumor size but not with proliferative activity of colorectal adenomas. Am J Pathol 156: 865–870.
9.
Brabletz, T., A. Jung, S. Dag, F. Hlubek, T. Kirchner (1999) β-Catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 155: 1033–1038.
10.
Brabletz, T., A. Jung, K. Hermann, K. Gunther, W. Hohenberger, T. Kirchner (1998) Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract 194: 701–704.
11.
Brabletz, T., A. Jung, S. Reu, M. Porzner, F. Hlubek, L. Kunz-Schughart, R. Knuechel, T. Kirchner (2001) Variable beta-catenin expression in colorectal cancer indicates a tumor progression driven by the tumor environment. Proc Natl Acad Sci USA 98: 10356–10361.
12.
Cavallo, R.A., R.T. Cox, M.M. Moline, J. Roose, G.A. Polevoy, H. Clevers, M. Peifer, A. Bejsovec (1998) Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 395: 604–608.
13.
Clevers, H., M. van de Wetering (1997) TCF/LEF factor earn their wings. Trends Genet 13: 485–489.
14.
Conacci-Sorrell, M., I. Simcha, T. Ben-Yedidia, J. Blechman, P. Savagner, A. Ben-Ze’ev (2003) Autoregulation of E-cadherin expression by cadherin-cadherin interactions: The roles of beta-catenin signaling, Slug, and MAPK. J Cell Biol 163: 847–857.
15.
Crawford, H.C., B.M. Fingleton, L.A. Rudolph-Owen, K.J. Heppner Goss, B. Rubinfeld, P. Polakis, L.M. Matrisian (1999) The metalloproteinase Matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 18: 2883–2891.
16.
Dihlmann, S., J. Gebert, A. Siermann, C. Herfarth, M. von Knebel Doeberitz (1999) Dominant negative effect of the APC1309 mutation: A possible explanation for genotype-phenotype correlations in familial adenomatous polyposis. Cancer Res 59: 1857–1860.
17.
Eger, A., A. Stockinger, B. Schaffhauser, H. Beug, R. Foisner (2000) Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity. J Cell Biol 148: 173–188.
18.
Freier, S., O. Weiss, M. Eran, A. Flyvbjerg, R. Dahan, I. Nephesh, T. Safra, E. Shiloni, I. Raz (1999) Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut 44: 704–708.
19.
Fujita, M., Y. Furukawa, T. Tsunoda, T. Tanaka, M. Ogawa, Y. Nakamura (2001) Up-regulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the beta-catenin/T-cell factor complex, in colorectal carcinomas. Cancer Res 61: 7722–7726.
20.
Gaire, M., Z. Magbanua, S. McDonnell, L. McNeil, D.H. Lovett, L.M. Matrisian (1994) Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J Biol Chem 269: 2032–2040.
21.
Galzie, Z., D.G. Fernig, J.A. Smith, G.J. Poston, A.R. Kinsella (1997) Invasion of human colorectal carcinoma cells is promoted by endogenous basic fibroblast growth factor. Int J Cancer 71: 390–395.
22.
Gavert, N., M. Conacci-Sorrell, D. Gast, A. Schneider, P. Altevogt, T. Brabletz, A. Ben-Ze’ev (2005) L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol, 168: 633–642.
23.
Gradl, D., M. Kuhl, D. Wedlich (1999) The Wnt/Wg signal transducer beta-catenin controls fibronectin expression. Mol Cell Biol 19: 5576–5587.
24.
Groden, J., A. Thliveris, W. Samowitz, M. Carlson, L. Gelbert, H. Albertsen, G. Joslyn, J. Stevens, L. Spirio, M. Robertson, et al. (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66: 589–600.
25.
Hassan, A.B., J.A. Howell (2000) Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res 60: 1070–1076.
26.
Hlubek, F., A. Jung, N. Kotzor, T. Kirchner, T. Brabletz (2001) Expression of the invasion factor laminin γ2 in colorectal carcinomas is regulated by β-catenin. Cancer Res 61: 8089–8093.
27.
Hovanes, K., T.W. Li, J.E. Munguia, T. Truong, T. Milovanovic, J. Lawrence Marsh, R.F. Holcombe, M.L. Waterman (2001) Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 28: 53–57.
28.
Huang, J., N. Papadopoulos, A.J. McKinley, S.M. Farrington, L.J. Curtis, A.H. Wyllie, S. Zheng, J.K. Willson, S.D. Markowitz, P. Morin, K.W. Kinzler, B. Vogelstein, M.G. Dunlop (1996) APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci USA 93: 9049–9054.
29.
Huelsken, J., R. Vogel, B. Erdmann, G. Cotsarelis, W. Birchmeier (2001) Beta-catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 105: 533–545.
30.
Inomata, M., A. Ochiai, S. Akimoto, S. Kitano, S. Hirohashi (1996) Alteration of beta-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res 56: 2213–2217.
31.
Jass, J.R., M. Barker, L. Fraser, M.D. Walsh, V.L. Whitehall, B. Gabrielli, J. Young, B.A. Leggett (2003) APC mutation and tumour budding in colorectal cancer. J Clin Pathol 56: 69–73.
32.
Jung, A., M. Schrauder, U. Oswald, C. Knoll, P. Sellberg, R. Palmqvist, G. Niedobitek, T. Brabletz, T. Kirchner (2001) The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D(1), and p16(INK4A) and is a region of low proliferation. Am J Pathol 159: 1613–1617.
33.
Kedinger, M., I. Duluc, C. Fritsch, O. Lorentz, M. Plateroti, J.N. Freund (1998) Intestinal epithelial-mesenchymal cell interactions. Ann NY Acad Sci 859: 1–17.
34.
Kinzler, K.W., M.C. Nilbert, L.K. Su, B. Vogelstein, T.M. Bryan, D.B. Levy, K.J. Smith, A.C. Preisinger, P. Hedge, D. McKechnie, et al. (1991) Identification of FAP locus genes from chromosome 5q21. Science 253: 661–665.
35.
Kirchner, T., T. Brabletz (2000a) Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence: Analogies with embryonic gastrulation. Am J Pathol 157: 1113–1121.
36.
Kirchner, T., T. Brabletz (2000b) Patterning and nuclear beta-catenin expression in the colonic adenoma-carcinoma sequence: Analogies with embryonic gastrulation. Am J Pathol 157: 1113–1121.
37.
Korinek, V., N. Barker, P. Moerer, E. van Donselaar, G. Huls, P.J. Peters, H. Clevers (1998) Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 19: 379–383.
38.
Korinek, V., N. Barker, P.J. Morin, D. van Wichen, R. de Weger, K.W. Kinzler, B. Vogelstein, H. Clevers (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC–/– colon carcinoma. Science 275: 1784–1787.
39.
Lickert, H., C. Domon, G. Huls, C. Wehrle, I. Duluc, H. Clevers, B.I. Meyer, J.N. Freund, R. Kemler (2000) Wnt/(beta)-catenin signaling regulates the expression of the homeobox gene Cdx1 in embryonic intestine. Development 127: 3805–3813.
40.
Liotta, L.A., E.C. Kohn (2001) The microenvironment of the tumour-host interface. Nature 411: 375–379.
41.
Liotta, L.A., W.G. Stetler-Stevenson (1991) Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 51: 5054s–5059s.
42.
Liu, D., I. el-Hariry, A.J. Karayiannakis, J. Wilding, R. Chinery, W. Kmiot, P.D. McCrea, W.J. Gullick, M. Pignatelli (1997) Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest 77: 557–563.
43.
Logan, C.Y., J.R. Miller, M.J. Ferkowicz, D.R. McClay (1999) Nuclear beta-catenin is required to specify vegetal cell fates in the sea urchin embryo. Development 126: 345–357.
44.
Mariadason, J.M., M. Bordonaro, F. Aslam, L. Shi, M. Kuraguchi, A. Velcich, L.H. Augenlicht (2001) Down-regulation of beta-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res 61: 3465–3471.
45.
Marotta, A., C. Tan, V. Gray, S. Malik, S. Gallinger, J. Sanghera, B. Dupuis, D. Owen, S. Dedhar, B. Salh (2001) Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene 20: 6250–6257.
46.
Morali, O.G., V. Delmas, R. Moore, C. Jeanney, J.P. Thiery, L. Larue (2001) IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 20: 4942–4950.
47.
Morin, P.J., A.B. Sparks, V. Korinek, N. Barker, H. Clevers, B. Vogelstein, K.W. Kinzler (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787–1790.
48.
Naishiro, Y., T. Yamada, A.S. Takaoka, R. Hayashi, F. Hasegawa, K. Imai, S. Hirohashi (2001) Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of beta-catenin/T-cell factor 4-mediated gene transactivation. Cancer Res 61: 2751–2758.
49.
Nguyen, B.P., M.C. Ryan, S.G. Gil, W.G. Carter (2000) Deposition of laminin 5 in epidermal wounds regulates integrin signaling and adhesion. Curr Opin Cell Biol 12: 554–562.
50.
Nishita, M., M.K. Hashimoto, S. Ogata, M.N. Laurent, N. Ueno, H. Shibuya, K.W. Cho (2000) Interaction between Wnt and TGF-beta signalling pathways during formation of Spemann’s organizer. Nature 403: 781–785.
51.
Noe, V., B. Fingleton, K. Jacobs, H.C. Crawford, S. Vermeulen, W. Steelant, E. Bruyneel, L.M. Matrisian, M. Mareel (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114: 111–118.
52.
Novak, A., S.C. Hsu, C. Leung-Hagesteijn, G. Radeva, J. Papkoff, R. Montesano, C. Roskelley, R. Grosschedl, S. Dedhar (1998) Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc Natl Acad Sci USA 95: 4374–4379.
53.
Oyama, T., Y. Kanai, A. Ochiai, S. Akimoto, T. Oda, K. Yanagihara, A. Nagafuchi, S. Tsukita, S. Shibamoto, F. Ito, et al. (1994) A truncated beta-catenin disrupts the interaction between E-cadherin and alpha-catenin: A cause of loss of intercellular adhesiveness in human cancer cell lines. Cancer Res 54: 6282–6287.
54.
Palmqvist, R., J.N. Rutegard, B. Bozoky, G. Landberg, R. Stenling (2000) Human colorectal cancers with an intact p16/Cyclin D1/pRb pathway have up-regulated p16 expression and decreased proliferation in small invasive tumor clusters. Am J Pathol 157: 1947–1953.
55.
Persad, S., A.A. Troussard, T.R. McPhee, D.J. Mulholland, S. Dedhar (2001) Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 153: 1161–1174.
56.
Riese, J., X. Yu, A. Munnerlyn, S. Eresh, S.C. Hsu, R. Grosschedl, M. Bienz (1997) LEF-1, a nuclear factor coordinating signaling inputs from wingless and decapentaplegic. Cell 88: 777–787.
57.
Rockman, S.P., S.A. Currie, M. Ciavarella, E. Vincan, C. Dow, R.J. Thomas, W.A. Phillips (2001) Id2 is a target of the beta-catenin/TCF pathway in colon carcinoma. J Biol Chem 25: 25.
58.
Ropponen, K.M., M.J. Eskelinen, P.K. Lipponen, E. Alhava, V.M. Kosma (1998) Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol 33: 301–309.
59.
Rubinfeld, B., B. Souza, I. Albert, O. Muller, S.H. Chamberlain, F.R. Masiarz, S. Munemitsu, P. Polakis (1993) Association of the APC gene product with beta-catenin. Science 262: 1731–1734.
60.
Schuhmacher, C., I. Becker, S. Oswald, M.J. Atkinson, H. Nekarda, K.F. Becker, J. Mueller, J.R. Siewert, H. Hofler (1999) Loss of immunohistochemical E-cadherin expression in colon cancer is not due to structural gene alterations. Virchows Arch 434: 489–495.
61.
Shtutman, M., J. Zhurinsky, I. Simcha, C. Albanese, M. D’Amico, R. Pestell, A. Ben-Ze’ev (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522–5527.
62.
Sordat, I., F.T. Bosman, G. Dorta, P. Rousselle, D. Aberdam, A.L. Blum, B. Sordat (1998) Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia. J Pathol 185: 44–52.
63.
Tetsu, O., F. McCormick (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422–426.
64.
Thiery, J.P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442–454.
65.
Wielenga, V.J., R. Smits, V. Korinek, L. Smit, M. Kielman, R. Fodde, H. Clevers, S.T. Pals (1999) Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154: 515–523.
66.
Woodhouse, E.C., R.F. Chuaqui, L.A. Liotta (1997) General mechanisms of metastasis. Cancer 80: 1529–1537.
67.
Zhang, T., T. Otevrel, Z. Gao, S.M. Ehrlich, J.Z. Fields, B.M. Boman (2001a) Evidence that APC regulates survivin expression: A possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 61: 8664–8667.
68.
Zhang, X., J.P. Gaspard, D.C. Chung (2001b) Regulation of vascular endothelial growth factor by the WNT and K-ras pathways in colonic neoplasia. Cancer Res 61: 6050–6054.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.